Surprising Results: Dapirolizumab Pegol Shows Promise in Phase 3 SLE Study, After Phase 2 Failure
Dapirolizumab pegol plus standard-of-care treatment met the primary endpoint in a Phase 3 study of moderate-to-severe systemic lupus erythematosus (SLE), according to topline results from PHOENYCS GO. The results are considered surprising since dapirolizumab pegol, a novel Fc-free anti-CD40L drug candidate, failed in an earlier Phase 2 study. In PHOENYCS GO, dapirolizumab pegol plus standard-of-care […]